United we stand
double targeting of CD79B and CD20 in diffuse large B-cell lymphoma
Informazioni aggiuntive
Autori
Tarantelli C.,
Bertoni F.
Tipo
Articolo pubblicato in rivista scientifica
Anno
2022
Lingua
Inglese
Sommario
Polatuzumab vedotin is antibody-drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymphoma cells exposed to polatuzumab vedotin and to rituximab and on potential mechanism of resistance to the ADC.
Parole chiave
Antibody-drug conjugate, Lymphoma, MMAE, Polatuzumab vedotin, Resistance, Rituximab
Periodico
British Journal of Haematology
Volume
199
Pagine (o numero dell’articolo)
169–170
Diffusione
Licenza
CC BY-NC-ND
Visibilità
Pubblico
Status open access
Hybrid
